Table 1.
Clinical associations with ALKBH5 combined protein expression in the Nottingham invasive breast carcinoma series
| Parameters | ALKBH5 protein Expression | ||
|---|---|---|---|
| Low (%) | High (%) | p-value | |
| Age | |||
| < 50 years | 52 (12.5) | 364 (87.5) | 0.609 |
| ≥ 50 years | 122 (13.5) | 780 (86.5) | |
| Tumour size | |||
| < 2 cm | 90 (11.6) | 688 (88.4) | 0.035 |
| ≥ 2 cm | 84 (15.6) | 456 (84.4) | |
| Grade | |||
| 1 | 18 (10.2) | 158 (89.8) | 0.04 |
| 2 | 59 (11.3) | 465 (88.7) | |
| 3 | 97 (15.7) | 521 (84.3) | |
| Stage | |||
| 1 | 91 (11.5) | 703 (88.5) | 0.012 |
| 2 | 53 (14.1) | 323 (85.9) | |
| 3 | 30 (20.3) | 118 (79.7) | |
| Tubule formation | |||
| 1 | 7 (10.1) | 62 (89.9) | < 0.001 |
| 2 | 32 (8.2) | 359 (91.8) | |
| 3 | 135 (15.7) | 723 (84.3) | |
| Pleomorphism | |||
| 1 | 0 (0) | 15 (100) | 0.315 |
| 2 | 48 (13.4) | 311 (86.6) | |
| 3 | 126 (13.3) | 818 (86.7) | |
| Mitosis | |||
| 1 | 69 (11.5) | 533 (88.5) | 0.194 |
| 2 | 37 (13.7) | 233 (86.3) | |
| 3 | 68 (15.2) | 378 (84.8) | |
| Multifocality | |||
| No | 124 (12.4) | 876 (87.6) | 0.066 |
| Yes | 50 (15.7) | 268 (84.3) | |
| Tumour type | |||
| NST | 117 (13.2) | 767 (86.8) | 0.016 |
| ILC, including lobular mixed | 20 (19.2) | 84 (80.8) | |
| Mixed NST and Iobular | 12 (14.8) | 69 (85.2) | |
| Mixed NST and special type | 4 (10.5) | 34 (89.5) | |
| Other Special tumour type including Mucinous, papillary, micropapillary, cribriform and adenoidcystic carcinoma | 1 (11.1) | 8 (88.9) | |
| Metaplastic carcinoma | 2 (66.7) | 1 (33.3) | |
| Tubular and tubular mixed | 18 (9) | 181 (91) | |
| Vascular invasion | |||
| Negative | 110 (12) | 806 (88) | 0.033 |
| Positive | 64 (15.9) | 338 (84.1) | |
| Associated DCIS | |||
| Negative | 22 (10.9) | 179 (89.1) | 0.173 |
| Positive | 152 (13.7) | 960 (86.3) | |
| LCIS | |||
| Negative | 148 (13.1) | 983 (86.9) | 0.252 |
| Positive | 26 (14.3) | 156 (85.7) | |
| Lymph node status | |||
| Negative | 91 (11.5) | 703 (88.5) | 0.015 |
| Positive | 83 (15.8) | 441 (84.2) | |
| ER | |||
| Negative | 55 (20.1) | 219 (79.9) | < 0.001 |
| Positive | 118 (11.3) | 925 (88.7) | |
| PgR | |||
| Negative | 91 (17) | 444 (83) | < 0.001 |
| Positive | 79 (10.3) | 691 (89.7) | |
| HER2 | |||
| Negative | 144 (12.7) | 990 (87.3) | 0.12 |
| Positive | 28 (15.5) | 153 (84.5) | |
| Triple negative | |||
| No | 135 (12.1) | 978 (87.9) | 0.009 |
| Yes | 36 (19) | 153 (81) | |
| Ki67 index groups | |||
| < 15 Hscore | 59 (12.1) | 430 (87.9) | 0.356 |
| ≥ 15 Hscore | 69 (14.1) | 422 (85.9) | |
| Molecular classes | |||
| Luminal types combined | 118 (11.3) | 925 (88.7) | < 0.001 |
| HER2 enriched | 17 (24.3) | 53 (75.7) | |
| TNBC | 36 (19) | 153 (81) | |
| Nottingham Prognostic Index | |||
| Good prognostic group | 41 (9.8) | 378 (90.2) | 0.006 |
| Moderate prognostic group | 92 (13.6) | 582 (86.4) | |
| Poor prognostic group | 41 (18.2) | 184 (81.8) | |
| Menopausal status | |||
| Pre | 56 (12) | 410 (88) | 0.135 |
| Post | 118 (13.8) | 734 (86.2) | |
| Chemotherapy | |||
| Non treated | 92 (11) | 745 (89) | 0.004 |
| Treated | 82 (17.1) | 398 (82.9) | |
| Endocrine therapy | |||
| Non treated | 70 (16.4) | 357 (83.6) | 0.013 |
| Treated | 104 (11.7) | 787 (88.3) | |
| Radiotherapy local | |||
| Non treated | 50 (13.4) | 322 (86.6) | 0.206 |
| Treated | 124 (13.1) | 822 (86.9) | |
| Radiotherapy LNs | |||
| Non treated | 123 (12.1) | 894 (87.9) | 0.02 |
| Treated | 51 (16.9) | 250 (83.1) | |
| Biological therapy | |||
| Non treated | 130 (13) | 873 (87) | 0.34 |
| Treated | 10 (14.3) | 60 (85.7) | |
Statistically significant associations are highlighted in bold